Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07894666
Recruiting Observational

French Validation of the SAHOT Outcome Scale After Subarachnoid Haemorrhage

NCT07894666 · tracked via the Priya Life Science France tracker
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Started
2026-09-28
Last updated
2026-10-26

Condition(s) studied

Subarachnoid Hemorrhage

Study summary

Survivors of subarachnoid haemorrhage (SAH) frequently experience cognitive, psychological, physical and social sequelae, but no French-language instrument covers all these dimensions. The SAHOT (Subarachnoid Haemorrhage Outcome Tool), developed and validated in English, is a SAH-specific patient-reported outcome measure. This prospective single-centre cohort study aims to validate the French translation of the SAHOT in adult patients seen at a follow-up consultation within 12 months after a SAH of any aetiology. The primary objective is to assess the internal consistency of the French SAHOT. Seventy patients will be included; accompanying relatives may also be included to complete a proxy version of the questionnaire.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria (patients): * Age over 18 years * Subarachnoid haemorrhage of any aetiology * Onset less than 12 months before inclusion * Seen in consultation at the Hôpital Fondation Adolphe de Rothschild * Judged able to complete a self-administered questionnaire by the evaluating clinician * Informed and not opposed to participation (or relative's non-opposition if the patient is under guardianship and/or unable to consent) Inclusion Criteria (relatives): * Age over 18 years * Relative / caregiver of a patient with subarachnoid haemorrhage within the previous 12 months * Attending the follow-up consultation of an included patient * Informed and not opposed to participation Exclusion Criteria (patients and relatives): * Non-French-speaking * Psychiatric disorder judged incompatible with completion of the questionnaires by the investigator

Primary outcome measure(s)

  • Internal consistency of the French version of the SAHOT — At inclusion (follow-up consultation within 12 months after subarachnoid haemorrhage)

Trial sites (1)

FacilityCityRegionStatus
Hôpital Fondation Adolphe de Rothschild Paris France Recruiting

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) Recruiting
Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis Recruiting
Incidence of Myopia in a Prospective Cohort of Emmetropic Children and Associated Ocular and Environmental Factors Recruiting
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim) Recruiting
Medico-economic Evaluation of Immediately Sequential Bilateral Cataract Surgery Compared With Delayed Sequential Cataract Surgery in France Recruiting

Other trials for the same condition

Strategies for Weaning From External Ventricular Drainage Starting soon
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage Active, not recruiting
Brain PERfusion Evaluation by Contrast-Enhanced UltraSound Recruiting
Impact of Early Mobilization on SAH Patients Physiological Parameters Starting soon
Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07894666 on ClinicalTrials.gov ↗ ← All trials in France